Detalles de la búsqueda
1.
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Cancer Immunol Immunother;
73(4): 72, 2024 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38430405
2.
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
Blood;
137(21): 2947-2957, 2021 05 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33259592
3.
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
Bioorg Med Chem;
28(2): 115227, 2020 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31862310
4.
BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5.
Blood Adv;
7(17): 5108-5121, 2023 09 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37184294
5.
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma.
Mol Cancer Ther;
22(10): 1154-1165, 2023 10 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37486983
6.
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Clin Cancer Res;
28(22): 4871-4884, 2022 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36044531
7.
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells.
NPJ Precis Oncol;
6(1): 95, 2022 Dec 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-36575215
8.
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
J Hematol Oncol;
14(1): 186, 2021 11 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34742344
9.
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Eur J Cancer;
146: 115-124, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33601323
10.
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer;
139: 135-148, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32992153
11.
3-amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile.
Bioorg Med Chem Lett;
19(3): 701-5, 2009 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19114305
12.
Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
Mol Cancer Ther;
18(5): 909-919, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30872381
13.
Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer.
Bioorg Med Chem Lett;
18(17): 4794-7, 2008 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18694641
14.
BRD4 facilitates replication stress-induced DNA damage response.
Oncogene;
37(28): 3763-3777, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29636547
15.
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.
PLoS One;
13(7): e0200826, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30036377
16.
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
Cancer Cell;
33(3): 401-416.e8, 2018 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29533782
17.
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer.
Cancer Immunol Res;
6(10): 1234-1245, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30087114
18.
Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors.
Clin Cancer Res;
23(4): 1025-1035, 2017 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28073847
19.
Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Mol Cancer Ther;
16(6): 1031-1040, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28292940
20.
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).
J Med Chem;
59(17): 7801-17, 2016 09 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27528113